Earkart Limited
Earkart Manufacture and distribute modern hearing aids and related accessories at affordable price across India. Along with our own manufactured hearing aid, we also trade in hearing aid, parts and accessories of other brands manufactured in India and abroad.(Source : 202509 Prospectus Page No: 20)
- Market Cap ₹ 168 Cr.
- Current Price ₹ 122
- High / Low ₹ 266 / 114
- Stock P/E 31.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 45.1 %
- ROE 41.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Cons
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 5.66 | 28.92 | 31.75 | 43.11 | |
| 5.52 | 27.29 | 28.17 | 33.32 | |
| Operating Profit | 0.14 | 1.63 | 3.58 | 9.79 |
| OPM % | 2.47% | 5.64% | 11.28% | 22.71% |
| 0.04 | 0.05 | 0.21 | 0.09 | |
| Interest | 0.01 | 0.08 | 0.36 | 0.44 |
| Depreciation | 0.06 | 0.15 | 0.19 | 0.42 |
| Profit before tax | 0.11 | 1.45 | 3.24 | 9.02 |
| Tax % | 0.00% | 9.66% | 5.86% | 23.61% |
| 0.11 | 1.31 | 3.06 | 6.88 | |
| EPS in Rs | 22.00 | 262.00 | 612.00 | 6.59 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 97% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 297% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 42% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 10.44 | 13.75 |
| Reserves | 4.72 | 6.49 | 12.97 | 9.48 | 52.31 |
| 0.27 | 1.23 | 4.02 | 4.96 | 5.62 | |
| 0.91 | 6.96 | 2.21 | 5.41 | 6.50 | |
| Total Liabilities | 5.95 | 14.73 | 19.25 | 30.29 | 78.18 |
| 0.22 | 0.25 | 1.06 | 1.17 | 1.61 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.46 | 0.10 | 0.19 | 0.83 | 0.83 |
| 4.27 | 14.38 | 18.00 | 28.29 | 75.74 | |
| Total Assets | 5.95 | 14.73 | 19.25 | 30.29 | 78.18 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -2.83 | -0.30 | -1.00 | 0.71 | |
| -1.78 | 0.40 | -1.29 | -1.32 | |
| 4.68 | 0.41 | 3.08 | -0.41 | |
| Net Cash Flow | 0.07 | 0.51 | 0.80 | -1.01 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 104.47 | 59.32 | 72.89 | 157.23 |
| Inventory Days | 138.26 | 100.90 | 113.12 | 95.52 |
| Days Payable | 92.17 | 107.33 | 19.28 | 44.04 |
| Cash Conversion Cycle | 150.56 | 52.89 | 166.73 | 208.70 |
| Working Capital Days | 192.17 | 60.83 | 108.06 | 139.02 |
| ROCE % | 23.89% | 29.02% | 45.13% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|
| Revenue Mix - Government Sector % |
|
|||
| Large Government Orders (ALIMCO/GeM) Units |
||||
| Revenue Mix - Private Sector % |
||||
| Shop-in-Shop (SIS) Clinics Number |
||||
| Annual Production Capacity (Hearing Aids) Units |
||||
| Dealer Partners Number |
||||
Documents
Announcements
-
Board Meeting Intimation for Prior Intimation Of The Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI LODR Regulations')- Board Meeting To Be Held On 30Th March 2026
1d - Board meeting on 30 Mar 2026 to consider varying IPO proceeds utilization and extending utilization timeline.
-
Board Meeting Outcome for Outcome Of The Board Meeting Called On Shorter Notice Along With Clarification
11 Mar - Board (11 Mar 2026) approved land acquisition and acquisition of a pharmaceutical business; short-notice meeting clarified.
-
Announcement under Regulation 30 (LODR)-Acquisition
26 Feb - Earkart Inc. incorporated Delaware (20 Jan 2026); EIN Feb 20 2026; 100% ownership, 1,000 $0.1 shares; US audiology platform.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
14 Feb - Earkart awarded ₹4,12,76,400 GeM government supply order for BTE hearing aids by ALIMCO on 14 Feb 2026.
-
Submission Of Transcript Of Valueportal Event Held On Tuesday, January 20, 2026 At 14:00 P.M.
23 Jan - Valueportal transcript (20 Jan 2026): Omni patent, FY revenue Rs43cr, 1.5 lakh units, 80 clinics, 1,500-clinic target.
Annual reports
No data available.
Concalls
-
Jan 2026TranscriptAI SummaryPPTREC
-
Dec 2025Transcript PPT
Business Profile[1]
Earkart manufactures and distributes modern hearing aids (BTE & RIC) and accessories, trades third-party hearing aids and parts, and also supplies mobility aids (foldable walkers) and educational/therapy kits (MSIED and TLM) for children with disabilities.